Felix Feng
Overview
Explore the profile of Felix Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1638
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, et al.
Lancet Oncol
. 2023 Nov;
24(11):1266-1276.
PMID: 37922930
Background: Checkpoint inhibitors have been shown to have limited activity in patients with metastatic castration-resistant prostate cancer. We aimed to determine whether a single dose of lutetium-177 [Lu]-prostate-specific membrane antigen...
12.
Sutera P, Shetty A, Song Y, Hodges T, Hoang T, Rana Z, et al.
Eur Urol Oncol
. 2023 Aug;
7(2):241-247.
PMID: 37558543
Background: Standard of care management for synchronous metastatic castration-sensitive prostate cancer (mCSPC) includes androgen deprivation therapy with a second-generation antiandrogen therapy and/or docetaxel. Recently, randomized data have demonstrated that prostate-directed...
13.
Feng F, Miladinovic B, Zhang K, Dignam J, Wang D, Yu M, et al.
Eur Urol
. 2023 Jul;
84(3):331-340.
PMID: 37393115
Background: Early endpoints in clinical trials of high-risk localized prostate cancer (HRLPC) that resemble those monitored in real-world practice could expedite clinical development. Objective: To assess the association of prostate-specific...
14.
Sutera P, Skinner H, Witek M, Mishra M, Kwok Y, Davicioni E, et al.
Semin Radiat Oncol
. 2023 Jun;
33(3):232-242.
PMID: 37331778
Histopathology and clinical staging have historically formed the backbone for allocation of treatment decisions in oncology. Although this has provided an extremely practical and fruitful approach for decades, it has...
15.
de Jong A, Danyi A, van Riet J, de Wit R, Sjostrom M, Feng F, et al.
Nat Commun
. 2023 Apr;
14(1):1968.
PMID: 37031196
Response to androgen receptor signaling inhibitors (ARSI) varies widely in metastatic castration resistant prostate cancer (mCRPC). To improve treatment guidance, biomarkers are needed. We use whole-genomics (WGS; n = 155)...
16.
17.
Mell L, Pugh S, Jones C, Nelson T, Zakeri K, Rose B, et al.
Eur Urol
. 2023 Jan;
85(4):373-381.
PMID: 36710205
Background: Previous studies indicate that the benefit of short-term androgen deprivation therapy (ADT) with radiotherapy (RT) for prostate cancer depends on competing risks. Objective: To determine whether a quantitative method...
18.
Quinn T, Chapman D, Parzen J, Wahl D, McNamara A, Dess R, et al.
Pract Radiat Oncol
. 2022 Dec;
13(2):e166-e175.
PMID: 36503624
Purpose: Prognostic factors for prostate cancer include tumor, node, metastases stage, pretreatment prostate-specific antigen, and pathology (via Gleason score [GS] or grade group). Of these, GS yields the largest effect...
19.
Tran P, Lowe K, Tsai H, Song D, Hung A, Hearn J, et al.
J Clin Oncol
. 2022 Nov;
41(6):1307-1317.
PMID: 36367998
Purpose: We sought to investigate whether enzalutamide (ENZA), without concurrent androgen deprivation therapy, increases freedom from prostate-specific antigen (PSA) progression (FFPP) when combined with salvage radiation therapy (SRT) in men...
20.
Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al.
Nat Commun
. 2022 Oct;
13(1):6467.
PMID: 36309516
Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain insights into the underlying biology. Here,...